Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
04/06/2026 21:13
BRIEF-Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease June 4 (Reuters) - Fulcrum Therapeutics Inc FULC.O:
FULCRUM THERAPEUTICS - APPROVES RESTRUCTURING PLAN AFTER DISCONTINUING POCIREDIR FOR SICKLE CELL DISEASE - SEC FILING
FULCRUM THERAPEUTICS - TO REDUCE WORKFORCE BY 85% FROM 57 TO 9 EMPLOYEES, COMPLETION EXPECTED Q2 2026 - SEC FILING
FULCRUM THERAPEUTICS - EXPECTS AGGREGATE RESTRUCTURING CHARGES OF ABOUT $4.2 MILLION - SEC FILING
FULCRUM THERAPEUTICS - WORKFORCE REDUCTION COMMUNICATED JUNE 4, 2026; CHARGES TO BE INCURRED IN Q2 2026 - SEC FILING
Further company coverage: FULC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fulcrum Therapeutics
See all newsFulcrum Therapeutics, Inc. expected to post a loss of 14 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
U.S. STOCKS ON THE MOVE - KBR, Vista Energy, Fulcrum Therapeutics
Fulcrum to merge with Slate in all-stock deal after drug setback